Octreotide Results Timeline: What Studies Measured, and When

Octreotide is a prescription somatostatin analogue, available in short-acting subcutaneous and long-acting depot formulations depending on the country and product. This page does not describe how anyone should use it. What follows is a description of the measurement timeline found in published trials: which endpoints researchers chose, at which timepoints they assessed them, and in which populations. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment.

One point shapes everything below: there is no single "octreotide timeline." The compound has been studied in acute hospital settings where outcomes were counted in hours, and in oncology settings where the primary endpoint was imaging-confirmed progression assessed over months to years. Reading a timeline from one indication into another is not supported by the literature cited here.

Measurement Windows at a Glance

Hours to Days: Acute Hospital Settings

Acute variceal bleeding

The shortest measurement window in this citation set comes from a randomised controlled trial that compared one day versus five days of octreotide infusion for acute oesophageal variceal bleeding, with the comparison built directly into the duration of therapy (PMID 41090987). The design is informative on its own terms: researchers were testing whether the longer infusion window added anything over the shorter one, which means the clinically relevant assessment period was measured in days, not weeks (PMID 41090987). Readers should note that this was a hospital-based trial in patients undergoing endoscopic management, not an outpatient scenario.

Hepatorenal syndrome

A randomised trial compared terlipressin plus albumin against midodrine and octreotide plus albumin in hepatorenal syndrome, with reversal of the syndrome as the outcome of interest (PMID 25644760). Here octreotide was part of a combination regimen rather than a single agent, and the study was designed as a head-to-head comparison of two inpatient strategies (PMID 25644760). The relevant timeline was the duration of an acute treatment course under close monitoring.

Malignant bowel obstruction

The 2021 MASCC guideline update on medical management of malignant bowel obstruction in advanced cancer addressed octreotide among the pharmacological options reviewed, in a setting where symptom assessment typically occurs over days rather than months (PMID 34390398). A guideline synthesis of this kind reports the strength and consistency of available evidence rather than a per-patient timeline, and the document frames its recommendations accordingly (PMID 34390398).

Weeks: Acromegaly Biochemistry

Acromegaly trials are built around biochemical endpoints, chiefly IGF-1 and growth hormone, because those markers can be re-measured at defined visits. ACROINNOVA 1 was a randomised, double-blind, placebo-controlled phase 3 trial of an octreotide subcutaneous depot in acromegaly, structured with a randomised controlled phase followed by an open-label period (PMID 39378125). The two-phase structure is the point for timeline purposes: researchers measured the placebo-controlled signal over the blinded window and then continued observation in the open-label extension (PMID 39378125).

A related question in this literature is what happens when patients already biochemically controlled on injected somatostatin receptor ligands are switched to a different agent. One study reported that acromegaly disease control was maintained after switching from injected somatostatin receptor ligands to oral paltusotine (PMID 38828555), and the earlier ACROBAT Edge study examined safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly (PMID 36353760). These are switch studies, so the measured timeline is the interval over which biochemistry was tracked after a change in therapy, not a timeline of initial response (PMID 36353760).

For anyone reading these as a "how long until it works" answer: the trials measured laboratory values at protocol-defined visits. They did not, and could not, report when any individual patient noticed a change. Those are different questions, and only a prescribing clinician can address the second one for a specific person.

Months: Bleeding Reduction and Transfusion Burden

The OCEAN study was a multicentre randomised controlled trial comparing standard of care versus octreotide in angiodysplasia-related bleeding, with transfusion-related outcomes as the focus (PMID 38158089). Unlike the variceal bleeding trial, this design required a follow-up period long enough to count repeated bleeding events and transfusion requirements, which pushes the measurement window from days into months (PMID 38158089). The endpoint choice explains the timeline: cumulative transfusion need cannot be assessed in a single week.

Chylothorax

A clinical review in Current Opinion in Pulmonary Medicine surveyed the literature on octreotide and chylothorax (PMID 16825878). Reviews of this type summarise heterogeneous case reports and small series rather than a randomised timeline, and that review is explicitly framed as a synthesis of published experience rather than a controlled trial (PMID 16825878). Evidence of that grade does not support a defined response schedule.

Months to Years: Neuroendocrine Tumour Trials

The longest measurement windows in this citation set come from oncology. The PROMID study was a placebo-controlled, double-blind, prospective, randomised study of octreotide LAR for control of tumour growth in patients with metastatic neuroendocrine midgut tumours, with time to tumour progression as the endpoint (PMID 19704057). Because progression is defined by serial imaging, the trial's timeline was dictated by scan intervals across months, not by symptom reports (PMID 19704057). A later report from the same study presented long-term survival results, extending the observation period further (PMID 26731483).

Long-acting octreotide has also served as the comparator arm in radioligand trials. NETTER-1 compared ¹⁷⁷Lu-Dotatate plus long-acting octreotide against high-dose long-acting octreotide in patients with midgut neuroendocrine tumours, and the 2021 publication reported final overall survival and long-term safety results from that open-label randomised phase 3 trial (PMID 34793718). NETTER-2 applied a similar comparison in newly diagnosed, advanced grade 2-3 well-differentiated gastroenteropancreatic neuroendocrine tumours (PMID 38851203). In both, high-dose long-acting octreotide was the control arm, so the published numbers describe a comparison rather than octreotide's standalone trajectory (PMID 38851203).

Final overall survival analyses, by definition, require years of follow-up, the NETTER-1 long-term report is an example of how far the measurement horizon extends in this disease area (PMID 34793718).

Adverse Events: What Studies Report

Safety reporting follows the same timeline logic as efficacy reporting. The NETTER-1 publication was framed as a report of final overall survival and long-term safety, meaning adverse events were collected across an extended follow-up period rather than only during active treatment (PMID 34793718). NETTER-2, as a phase 3 randomised study with a high-dose long-acting octreotide control arm, likewise collected safety data within its randomised comparison (PMID 38851203).

In endocrinology, ACROINNOVA 1 reported safety alongside efficacy within its placebo-controlled phase 3 design (PMID 39378125), and ACROBAT Edge was explicitly designed to report safety and efficacy of switching injected SRLs to oral paltusotine (PMID 36353760). Guideline documents sit at a different level again: the 2021 MASCC update weighed benefits and harms across the evidence base when making its recommendations for malignant bowel obstruction (PMID 34390398). None of these sources supports a general statement about what any individual would experience, and the prescribing information plus a treating clinician remain the appropriate sources for that.

How to Read a Timeline Question Honestly

• The endpoint sets the clock. Rebleeding after endoscopy was assessed across a days-long infusion comparison (PMID 41090987); time to tumour progression required serial imaging over months (PMID 19704057).
• Trial-level ≠ person-level. PROMID's long-term survival report describes a randomised cohort, not a prediction for any one patient (PMID 26731483).
• Comparator arms are not monotherapy descriptions. High-dose long-acting octreotide functioned as the control in NETTER-2 (PMID 38851203).
• Review-level evidence is weaker. The chylothorax literature was summarised in a narrative review rather than a randomised trial (PMID 16825878).

Formulations and Why They Change the Question

Short-acting and long-acting formulations are studied differently. Acute trials used infusion protocols with duration itself as the randomised variable (PMID 41090987), while oncology and endocrinology trials used long-acting depot preparations assessed at scheduled visits, PROMID studied octreotide LAR (PMID 19704057), and ACROINNOVA 1 studied an octreotide subcutaneous depot (PMID 39378125). Comparing a depot study's month-scale schedule with an infusion study's day-scale schedule produces a misleading answer.

This page does not state doses, because the verified literature summarised here is cited at the level of design and endpoints rather than dosing schedules. Dosing is a prescribing decision. Anyone with a question about whether, when or how octreotide might be used should direct it to a licensed physician who can review their individual situation and the approved product labelling.

References

• Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update (Supportive Care in Cancer, 2021)
• [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study (Lancet, 2024)
• Octreotide and chylothorax (Current Opinion in Pulmonary Medicine, 2006)
• Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial (Gastroenterology, 2024)
• 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial (The Lancet Oncology, 2021)
• Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine (JCEM, 2024)
• Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group (JCO, 2009)
• One vs Five Days of Octreotide Infusion for Acute Esophageal Variceal Bleeding: A Randomized Controlled Trial (American Journal of Gastroenterology, 2026)
• Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival (Neuroendocrinology, 2017)
• Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1 (JCEM, 2025)
• ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly (JCEM, 2023)
• Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial (Hepatology, 2015)